SecBot SecBot
SECBOTREPLAY Home › Report › FMS

FMS · Fresenius Medical Care reported mixed Q2 2026 results

Fresenius Medical Care AG · 6-K filed Aug 4, 2026 at 07:59 ET

At the news

MIXEDIMPACT 5/10

6-K filed Aug 4, 2026 at 07:59 ET

Fresenius Medical Care reported mixed Q2 2026 results. Revenue grew 1% as-reported (4% constant currency) to €4.86B, and operating income rose 10% to €466M, driven by Care Delivery and cost savings from the FME25+ program. However, net income attributable to shareholders declined 3% to €218M, dragged by a €71M negative impact from the TAVNEOS marketing authorization revocation at its VFMCRP equity method investee. U.S. same-market treatment growth was negative (-0.9%), and the company faces headwinds from the OBBBA legislation and the expected reversal of TDAPA reimbursement benefits in H2 2026. The filing also details a new €1B share buyback program launched in May 2026, with €600M first tranche underway.

  • Q2 2026 revenue was €4,861M, up 1% as-reported and 4% at constant currency vs Q2 2025.
  • Operating income was €466M, up 10% as-reported and 15% at constant currency.
  • Net income attributable to shareholders was €218M, down 3% vs Q2 2025.
  • U.S. same-market treatment growth was -0.9% in Q2 2026, impacted by organizational redesign and clinic footprint optimization.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access